Fortitude Family Office’s Terns Pharmaceuticals TERN Stock Holding History

Fortitude Family Office’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-192	Closed	-$10.1K	–	2371
2026 Q1	$10.1K	Sell	192 -269	-58%	-$11K	﹤0.01%	655
2025 Q4	$18.6K	Hold	461	–	–	﹤0.01%	418
2025 Q3	$3.46K	Buy	461 +125	+37%	+$798	﹤0.01%	965
2025 Q2	$1.25K	Buy	+336	New	+$1.05K	﹤0.01%	1400
2024 Q1	–	Sell	-300	Closed	-$1.95K	–	1081
2023 Q4	$1.95K	Buy	+300	New	+$1.59K	﹤0.01%	876

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fortitude Family Office's TERN Position: Q2 2026 in Review

Fortitude Family Office sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 192 shares — an estimated $10.1K sold.

Fortitude Family Office first reported a position in TERN in Q4 2023 and held it in 5 quarters. The position peaked at $18.6K in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Fortitude Family Office reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Fortitude Family Office sold 192 Terns Pharmaceuticals shares in Q2 2026, an estimated $10.1K.
Fortitude Family Office first reported a position in Terns Pharmaceuticals in Q4 2023 and held it in 5 quarters.
Fortitude Family Office's Terns Pharmaceuticals position peaked at $18.6K in Q4 2025.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.